Novo Nordisk $3.3 billion acquisition of Dicerna Pharmaceuticals
We are advising Novo Nordisk on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
BDT Capital Partners acquires a majority interest in MJH Life Sciences
We are advising BDT Capital Partners on the transaction
Triple-S Management $900 million acquisition by GuideWell
We are advising Triple-S on the transaction
Adagio Therapeutics $356 million IPO
We advised the underwriters on the IPO and Nasdaq listing
RxSight $117.6 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Tenaya Therapeutics $207 million IPO
We advised the underwriters on the IPO and Nasdaq listing
SOPHiA GENETICS $234 million IPO and $20 million private placement
We advised SOPHiA GENETICS on its IPO, Nasdaq listing and concurrent private placement
TScan Therapeutics $100 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Sight Sciences $276 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Novo Nordisk acquisition of Neotope Neuroscience
We advised Novo Nordisk on the acquisition